REG - Genedrive PLC - Result of AGM

GenedriveAnnouncement

30/12/2024 12:01

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241230:nRSd6228Ra&default-theme=true

RNS Number : 6228R  Genedrive PLC  30 December 2024

genedrive plc

("genedrive" or the "Company")

 

Result of AGM

 

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company,
announces that at the Annual General Meeting, held today, all resolutions
proposed were duly passed.

 

For information, details of the proxy voting are shown below:

 

 Resolution  Votes For   Votes For              Votes Against  Votes Against          Vote Withheld

                         (as % of votes cast)                  (as % of votes cast)

 1           60,337,408  96.9%                  1,932,301      3.1%                   44,070
 2           54,051,527  89.5%                  6,370,692      10.5%                  1,891,560
 3           56,234,467  90.4%                  5,972,194      9.6%                   107,118
 4           56,232,855  90.4%                  5,973,806      9.6%                   107,118
 5           54,614,002  89.9%                  6,155,707      10.1%                  1,544,070
 6           56,585,659  90.9%                  5,684,050      9.1%                   44,070
 7           41,714,611  67.0%                  20,555,098     33.0%                  44,070
 8           58,270,899  93.6%                  3,980,810      6.4%                   62,070
 9           52,909,558  87.3%                  7,705,575      12.7%                  1,698,646
 10          49,491,977  81.7%                  11,079,156     18.3%                  1,742,646
 11          52,535,894  86.7%                  8,035,239      13.3%                  1,742,646

 

The full text of each of the resolutions is set out in the notice of Annual
General Meeting, copies of which are available on the Company's website
(www.genedriveplc.com (http://www.genedriveplc.com/) ).

 

Although all the resolutions were passed, the Board of genedrive notes that
more than 20% of votes were cast against the reappointment of one of the
directors.  While the Board believes that this director brings considerable
experience and expertise to the Board, it intends to engage with shareholders
to better understand their concerns on the resolution in question.

 

For further details please contact:

 

 genedrive plc                                     +44 (0)161 989 0245
 Gino Miele: CEO / Russ Shaw: CFO

 Peel Hunt LLP (Nominated Adviser and Broker)      +44 (0)20 7418 8900
 James Steel / Patrick Birkholm

 Walbrook PR Ltd (Media & Investor Relations)      +44 (0)20 7933 8780 or genedrive@walbrookpr.com
 Anna Dunphy                                        +44 (0)7876 741 001

 

About genedrive plc (http://www.genedriveplc.com
(http://www.genedriveplc.com/) )

 

genedrive plc is a pharmacogenetic testing company developing and
commercialising a low cost, rapid, versatile and simple to use point of need
pharmacogenetic platform for the diagnosis of genetic variants. This helps
clinicians to quickly access key genetic information that will aid them make
the right choices over the right medicine or dosage to use for an effective
treatment, particularly important in time-critical emergency care healthcare
paradigms. Based in the UK, the Company is at the forefront of Point of Care
pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on
how your individual genetics impact a medicines ability to work for you.
Therefore, by using pharmacogenetics, medicine choices can be personalised,
made safer and more effective. The Company has launched its two flagship
products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit,
both developed and validated in collaboration with NHS partners and deployed
on its point of care thermocycler platform. Both tests are single-use
disposable cartridges which are ambient temperature stable, circumventing the
requirement for cold chain logistics. The Directors believe the Genedrive®
MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on
antibiotic use in neonatal intensive care units within 26 minutes, ensuring
vital care is delivered, avoiding adverse effects potentially otherwise
encountered and with no negative impact on the patient care pathway. Its
CYP2C19 ID Kit which has no comparably positioned competitor currently allows
clinicians to make a decision on the use of Clopidogrel in stroke patients in
70 minutes, ensuring that patients who are unlikely to benefit from or suffer
adverse effects from Clopidogrel receive an alternative antiplatelet
therapeutic in a timely manner, ultimately improving outcomes. Both tests have
undergone review by the National Institute for Health and Care Clinical
Excellence ("NICE") and have been recommended for use in the UK NHS.

 

The Company has a clear commercial strategy focused on accelerating growth
through maximising in-market sales, geographic and portfolio expansion and
strategic M&A, and operates out of its facilities in Manchester.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGBBBDDBUXDGSG